Pulmonx Corporation (LUNG)

Market Cap	353.81M
Revenue (ttm)	83.79M
Net Income (ttm)	-56.39M
Shares Out	39.49M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,010,009
Open	8.91
Previous Close	8.78
Day's Range	8.63 - 9.35
52-Week Range	5.46 - 11.73
Beta	0.64
Analysts	Buy
Price Target	11.92 (+33.04%)
Earnings Date	Feb 19, 2025

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitat...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 1, 2020
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: LUNG
• Website: https://pulmonx.com

Financial Performance

In 2024, Pulmonx's revenue was $83.79 million, an increase of 22.01% compared to the previous year's $68.68 million. Losses were -$56.39 million, -7.31% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $11.92, which is an increase of 33.04% from the latest price.

Price Target

$11.92

(33.04% upside)

Analyst Consensus: Buy